Across TCGA pan-cancer cohorts, TRAV12-3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRAV12-3 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRAV12-3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAV12-3 expression acts as an unfavorable survival marker.

HNSC and SKCM are the cancer types where TRAV12-3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.139	0.663	<.001	48	view →
SKCM	DFS	Median	III,IV	0.238	0.652	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TRAV12-3 tumor-vs-normal RNA expression · all TRAV12-3 data types